mardi 17 mars 2020

Onco Actu du 17 mars 2020


4.2 DÉP., DIAG. & PRONO. - GÉNOME



DNA tests grow more vital in hereditary breast cancer treatments. They also raise unanswerable questions. [Washington Post]










4.9 DÉP., DIAG. & PRONO. - SEIN



Aging Out of the Mammogram [NY Times]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Cancer Drug with Better Staying Power and Reduced Toxicity Shows Promise in Preclinical Trials [University of Texas]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer [AstraZeneca]











AstraZeneca's lung cancer treatment fails to meet main goal [Reuters]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Merck's Keytruda pulled from England's Cancer Drugs Fund in bladder cancer [Fierce Pharma]











5.2.3 PHARMA - ÉCONOMIE



How are pharma supply chains reacting to COVID-19? Without info, it's hard to tell: analyst [Fierce Pharma]











6.7.2 APPLIS



App Detects Harsh Side Effect of Breast Cancer Treatment [Georgia Tech]